The immunomodulator fingolimod (FTY720) induces lymphopenia by inhibiting lymphocyte egress from thymus and secondary lymphoid organs (SLOs). It is phosphorylated mainly by sphingosine kinase (SK) 2 in vivo. FTY720-phosphate (FTY-P) activated and rapidly internalized S1P 1 , which is the major sphingosine 1-phosphate (S1P) receptor for mediating lymphocyte egress. Although FTY-P is thought to be the active metabolite for triggering the onset of lymphopenia, nonphosphorylated FTY720 was much more potent in inhibiting cellular calcium flux and splenocyte chemotaxis via S1P 1 than FTY-P after preincubation. Determination of both compounds by liquid chromatography coupled to mass spectrometry revealed efficient uptake and accumulation of FTY720 but not FTY-P by splenocytes. Coculture experiments of B and T cells with and without FTY720 pretreatment led to rapid cellular transfer and phosphorylation by mouse lymphocytes. The presence of FTY720 in lymphoid tissues of FTY720-treated SK2-deficient mice without onset of lymphopenia excluded a potential role of the nonphosphorylated compound for lymphocyte egress. Local concentrations of both phosphorylated and nonphosphorylated FTY720 were much higher in lymphoid tissues than in blood. Therefore, we conclude that cellular accumulation of FTY720 generates a reservoir in thymus and SLOs, leading to sustained FTY-P production and activation of S1P 1 within tissues.
FTY720 but not FTY-P by splenocytes. Coculture experiments of B and T cells with and without FTY720 pretreatment led to rapid cellular transfer and phosphorylation by mouse lymphocytes. The presence of FTY720 in lymphoid tissues of FTY720-treated SK2-deficient mice without onset of lymphopenia excluded a potential role of the nonphosphorylated compound for lymphocyte egress. Local concentrations of both phosphorylated and nonphosphorylated FTY720 were much higher in lymphoid tissues than in blood. Therefore, we conclude that cellular accumulation of FTY720 generates a reservoir in thymus and SLOs, leading to sustained FTY-P production and activation of S1P 1 within tissues.
The immunomodulator FTY720 shares structural similarities with sphingosine and is phosphorylated in vivo mainly by sphingosine kinase (SK) (Kharel et al., 2005; Zemann et al., 2006) . It induces lymphopenia by blocking S1P 1 receptormediated lymphocyte egress from thymus and SLOs (Brinkmann et al., 2002; Mandala et al., 2002) . Various studies with S1P 1 receptor-deficient mice evidenced that S1P 1 receptor expression on lymphocytes is required for their exit from lymphoid organs, indicating that stimulation of S1P 1 by its endogenous ligand sphingosine 1-phosphate (S1P) triggers the required signal for exit Matloubian et al., 2004) . This hypothesis however is challenged by pharmacological studies showing that agonists, but not antagonists, for S1P 1 are inducing lymphopenia in rodents (Wei et al., 2005; Foss et al., 2007) . A suggested explanation for the latter observation is the closure of postulated portals in the sinus-lining endothelium of lymph nodes by activation of S1P 1 on endothelial cells (Wei et al., 2005) . In both cases, S1P and other agonists for the S1P 1 receptor are inducers of lymphopenia either by activation-induced down-regulation of S1P 1 in lymphocytes or by activation of S1P 1 on endothelial cells.
FTY720 is considered to be a prodrug that needs to be phosphorylated by sphingosine kinases to its active form FTY-P. But nonphosphorylated FTY720 was also shown to have direct intracellular effects on cytosolic phospholipase A 2 , extracellular signal-regulated kinases 1 and 2, and serine/threonine protein kinase Akt (Coelho et al., 2007; Payne et al., 2007) . However, the fact that low dosages of FTY720 are inducing lymphopenia in wild-type, but not in SK2-deficient mice, proves that phosphorylation plays an important role for its blocking activity on lymphocyte egress (Kharel et al., 2005; Zemann et al., 2006) .
Besides the use of S1P 1 receptor agonists, alterations of endogenous levels of S1P as the natural ligand for S1P 1 also affect lymphocyte circulation. Treatment of mice with the vitamin B 6 antagonist and S1P-lyase inhibitor 4-deoxypyridoxine resulted in accumulation of S1P in lymphoid tissues, which is thought to abrogate the S1P gradient between lym-phoid organs with no or very low S1P levels and lymph and blood with high nanomolar S1P concentrations (Schwab et al., 2005) . According to the above-mentioned theories, pathological accumulation of S1P in lymphoid tissues may activate and prematurely down-regulate the S1P 1 receptor in lymphocytes, rendering them unresponsive to S1P, and stimulate the S1P 1 receptor on sinus-lining endothelial cells to close postulated portals. In contrast, depletion of S1P from blood and lymph by the induced deletion of SK1 and SK2, predominantly in hematopoietic and vascular endothelial cells in mice, also resulted in lymphopenia by abrogation of lymphocyte egress (Pappu et al., 2007) . Results from S1P supplementation studies, which should resemble the effect of pharmacological S1P 1 receptor agonists, are mixed. Whereas bolus injection of S1P did not alter lymphocyte circulation, intravenous infusion of 2 to 8 mg/kg/h induced lymphopenia (Brinkmann et al., 2002; Mandala et al., 2002) .
Obvious phenotypic discrepancies, such as the in vivo activity of S1P 1 receptor agonists (but not antagonists), receptor down-regulation in lymphocytes and stimulation on endothelial cells, the inability of single S1P injections to resemble agonist-induced lymphopenia, and receptor-mediated effects of FTY-P versus intracellular effects of nonphosphorylated FTY720 led us to investigate the characteristics of both compounds in more detail with regard to their contribution to the in vivo onset of lymphopenia and its mechanistic requirements.
Materials and Methods
Chemicals and Mice. S1P and 2-(2-methoxyethoxy)ethanol (2-MEE) were purchased from Sigma-Aldrich (Taufkirchen, Germany). N,N-Dimethylsphingosine (DMS) was purchased from Alexis (Grü nberg, Germany). Sphingosine (Sph) and 1,3-dihydroxy-2-amino-4-heptadecene (a 17-carbon analog of Sph; C17-Sph) were purchased from Otto Nordwald GmbH (Hamburg, Germany). Chemicals and solvents were purchased from Roth (Karlsruhe, Germany) if not stated otherwise. AAL(R/S), AFD(R/S), FTY720, and FTY-P were kindly provided by Volker Brinkmann (Novartis, Basel, Switzerland) (Brinkmann et al., 2002) . FTY-P, AAL(R/S), and AFD(R/S) were dissolved at a concentration of 50 mM in dimethyl sulfoxide/50 mM HCl and diluted with methanol to 1 mM FTY-P. FTY720 and S1P were dissolved in methanol to final concentrations of 1 mM. C57BL/6 mice were purchased from the Hannover Medical School Animal Facility (Hanover, Germany). SK2-deficient mice were kindly provided by Andreas Billich (Novartis).
Cell Culture. Serum, cell culture media, antibiotics, and supplements were purchased from PAA Laboratories GmbH (Coelbe, Germany), if not stated otherwise. Wild-type rat hepatoma HTC 4 cells and human S1P 1 G␣ i -expressing HTC 4 cells were cultured in Eagle's minimum essential medium with Earle's salts supplemented with 10% fetal calf serum (FCS), 1 mM sodium pyruvate, 2ϫ nonessential amino acids, 100 U/ml penicillin G, 100 g/ml streptomycin, and 2 mM L-glutamine. HTC 4 cells expressing human S1P 1 -hemagglutinin (HA) were cultured in the presence of 0.4 mg/ml G418 sulfate. Primary splenocytes were incubated in RPMI 1640 medium supplemented with 10% FCS, 100 U/ml penicillin G, 100 g/ml streptomycin, and 2 mM L-glutamine. Dephosphorylation of FTY-P was inhibited with a phosphatase inhibitor mix (2 mM imidazole, 1 mM sodium fluoride, 1.15 mM sodium molybdate, 1 mM sodium orthovanadate, and 4 mM sodium tartrate), which was added 1 h before addition of FTY-P. Phosphorylation of FTY720 was blocked by 10 M DMS, added 1 h before FTY720.
Calcium Flux. HTC 4 cells were harvested with trypsin (PAA Laboratories GmbH) and washed three times with Ca 2ϩ /Mg 2ϩ -free
Hanks' balanced salt solution (PAA Laboratories GmbH) supplemented with 10% charcoal-adsorbed FCS (PAA Laboratories GmbH). Then, we loaded 1 ϫ 10 7 cells/ml for 30 min at 37°C with 2.5 M Fura-2/acetoxymethyl ester (Calbiochem-Novabiochem, Bad Soden, Germany) in the same buffer. After three additional washing steps, we resuspended 2 ϫ 10 6 cells/ml in Ca 2ϩ -containing Hanks' balanced salt solution supplemented with 10% charcoal-adsorbed FCS. Increases in [Ca 2ϩ ] i were determined at 37°C in a 3-ml quartz-cuvette (Thermo Fisher Scientific GmbH, Dreieich, Germany) using the spectrofluorophotometer Hyper RF-5301PC (Shimadzu, Duisburg, Germany), with 335-nm excitation wavelength and 505-nm emission wavelength. Relative calcium responses after stimulation with 100 nM Sph, S1P, FTY720, FTY-P, AAL(R/S), or AFD(R/S) were normalized to the corresponding signal with 10 M ATP (Sigma-Aldrich) in each single experiment (ϭ100). Preincubation of HTC 4 cells was performed with 300 nM FTY720, FTY-P, AAL(R/S), or AFD(R/S) for 1 or 15 h.
Flow Cytometry. Cell staining and analysis were performed according to standard protocols. Surface expression of S1P 1 -HA on HTC 4 cells, which were incubated for 1 h at 37°C with 300 nM FTY720, FTY-P, AAL(R/S), or AFD(R/S), was analyzed by fluorescence-activated cell sorting (FACS) using the FACSCalibur system (BD Biosciences, Heidelberg, Germany). The N-terminal HA-epitope (peptide sequence, MGYPYDVPDYAGGP) was detected with the rat anti-HA antibody 3F10, kindly provided by Elisabeth Kremmer (GSF, Munich, Germany) and goat anti-rat Cy2-conjugated secondary antibody (Millipore Bioscience Research Reagents, Temecula, CA). Cell staining was performed with 12.5 g/ml rat anti-HA and 5 g/ml goat anti-rat-Cy2 in phosphate-buffered saline (PBS) at 4°C for 60 min. Blood was isolated by cardial puncture, and lymphocytes were counted with Flow Check Flow Cytometry Particles APC Maxi-Brite (Polysciences Europe GmbH, Eppelheim, Germany) after erythrocyte lysis and labeling with anti-CD3ε-fluorescein isothiocyanate and anti-CD45R-phycoerythrin (ImmunoTools, Friesoythe, Germany).
Lipid/FTY720 Extraction. Biological samples (1 ml of medium, 50 l of erythrocyte cell pellet, or 100 l of plasma) were adjusted to 1-ml sample volume with 1 M NaCl and transferred into a glass centrifuge tube. After addition of 1 ml of methanol (Baker, Griesheim, Germany) and 200 l of hydrochloric acid (Baker), the samples were vortexed. Chloroform (2 ml) was added, and the samples were vigorously vortexed for 2 min. After the samples were centrifuged for 3 min at 1900g, the lower chloroform phase was transferred to another glass centrifuge tube. The lipid extraction was repeated with 2 ml of chloroform, and the two chloroform phases were combined and vacuum-dried in a SpeedVac concentrator (Christ, Osterode, Germany) for 45 min at 50°C.
Sample Preparation for LC/MS/MS Analysis. The extracted lipids were dissolved in a methanol/chloroform mixture [4:1 (v/v)] and stored at Ϫ20°C. C17-Sph (200 pmol), used as the internal standard, was added before lipid extraction.
ESI LC/MS/MS Analysis. A QTrap triple-quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) interfaced with a Merck-Hitachi Elite LaChrom series 3.1.3 chromatograph and autosampler (VWR International GmbH, Darmstadt, Germany) was used for electrospray ionization (ESI) LC/MS/MS analysis. Positive ion ESI LC/MS/MS analysis together with postcolumn addition of 2-MEE was used for detection of all analytes. The multiple reaction monitoring transitions for the detection were as follows: C17-Sph, m/z 286/268; FTY720, m/z 308/255; and FTY-P, m/z 388/255.2. Liquid chromatographic resolution of all analytes was achieved using a Zorbax Extend-C18 column (2.1 ϫ 50 mm, 3.5 m; Agilent Technologies, Böblingen, Germany). The elution protocol for FTY720 and FTY-P was composed of a 9-min column equilibration with 10% solvent A (methanol), 40% solvent B (H 2 O), and 50% solvent C (100 mM HCl) followed by sample injection, a 1-min period with 50% solvent C, a 20-min period with 100% solvent A, and a 4-min period with 50% solvent B. Samples were infused into the ESI source through an electrode tube at a rate of 300 l/min together with 2-MEE at a rate of 100 l/min. Standard curves, with C17-Sph as the internal standard, were generated by adding increasing concentrations of the analytes to 300 pmol of C17-Sph. Linearity of the standard curves and correlation coefficients were obtained by linear regression analyses. All mass spectrometry analyses were performed using Analyst 1.4 (Applied Biosystems, Darmstadt, Germany).
Magnetic Bead Cell Sorting. Primary splenocytes were immunomagnetically separated using the magnetic cell sorting system (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the supplied protocol. Wild-type C57BL/6 splenocytes were isolated as described below, and 5 ϫ 10 6 T cells were preincubated with 1 M FTY720 for 1 h at 37°C followed by two washing steps with PBS and coculture of 5 ϫ 10 6 untreated B cells for 1 h at 37°C. Finally, T and B cells were separated again by magnetic bead sorting and separately analyzed by high-performance liquid chromatography (Andréani and Grä ler, 2006) . B cells were isolated using CD19 MicroBeads, and T cells were taken from the effluent.
Splenocyte Isolation. Spleens from mice were minced on ice and pushed through a 70-m mesh. Red blood cells were lysed in 138 mM NH 4 Cl, 1 mM KHCO 3 , and 0.1 mM EDTA for 5 min, and remaining splenocytes were washed three times with PBS supplemented with 10% FCS.
Transwell in Vitro Chemotaxis Assay. Migration of primary mouse splenocytes was analyzed in 24-well Transwell chambers (Corning Life Sciences, Lowell, MA) with 6.5-mm-diameter and 5-m pore polycarbonate filters, which were coated on the lower side for 16 h at 4°C with 600 l of 100 g/ml human collagen type IV (Sigma-Aldrich) in 0.5 M acetic acid, washed three times with 600 l of PBS, and air-dried. Splenocytes were isolated as described above, and 2 ϫ 10 6 cells were preincubated for 15 min at 37°C with 300 nM FTY720, FTY-P, AAL(R), or AFD(R). Cells were washed twice with PBS and resuspended in 100 l of RPMI 1640 medium supplemented with 0.1% fatty acid-free bovine serum albumin (United States Biological, Swampscott, MA) 100 U/ml penicillin G, 100 g/ml streptomycin, 2 mM L-glutamine, and 25 mM HEPES buffer, and then they were placed on the top of the Transwell inserts. The chemotactic stimulus of 600 l of 20 nM S1P in the same medium was added to the lower part of the chamber. Migration was performed for 4 h at 37°C in a humidified 5.0% CO 2 atmosphere incubator. Inserts were removed, and the number of migrated cells was assessed by flow cytometry using Flow Check Flow Cytometry Particles APC MaxiBrite (Polysciences Europe GmbH) as internal standard. To establish the number of cells that migrated nonspecifically, migration assays were performed in parallel in the absence of chemoattractant. Results are expressed as -fold increase of specific migration over unspecific migration without chemoattractant.
Results
To elucidate differences between phosphorylated and nonphosphorylated FTY720 on S1P 1 receptor signaling and surface expression, both compounds and their stereoselective analogs AAL(R/S) and AFD(R/S) were tested for their ability to induce cellular calcium flux ([Ca 2ϩ ] i ) and down-regulation of S1P 1 surface expression. HA-tagged S1P 1 receptor-expressing rat hepatoma HTC 4 cells (S1P 1 -HA HTC 4 ) were used for this purpose. Whereas only the phosphorylated compounds FTY-P and AFD(R) elicited immediate [Ca 2ϩ ] i (Fig.  1A) , both phosphorylated and nonphosphorylated substances down-regulated S1P 1 -HA surface expression within 1 h, except for the stereospecific isomers AAL(S) and AFD(S) (Fig.  1B) . Preincubation of S1P 1 -HA HTC 4 cells with FTY720 and FTY-P for 15 min resulted in 2 times more efficient downregulation of S1P 1 -HA by FTY-P than FTY720 (Fig. 1C) . Further incubation of treated S1P 1 -HA HTC 4 cells for 2 h, however, switched the efficiency of both compounds, with FTY720 being more effective in down-regulating S1P 1 -HA than FTY-P (Fig. 1C) .
To further dissect differences of phosphorylated and nonphosphorylated FTY720 on S1P 1 receptor-mediated cellular responses, S1P 1 -HA HTC 4 cells were preincubated with FTY720, FTY-P, AAL(R/S), and AFD(R/S) for 1 and for 15 h and subsequently tested for their S1P-elicited calcium responses. All nonphosphorylated compounds except AAL(S) efficiently inhibited [Ca 2ϩ ] i after preincubation for 1 and 15 h ( Fig. 2A) . Treatment of cells with the sphingosine kinase inhibitor DMS did not alter inhibition of [Ca 2ϩ ] i by FTY720 (Fig. 2A) . The phosphorylated analogs were similarly effective after 15-h preincubation, but they had only little inhibitory impact after 1-h preincubation ( Fig. 2A) . AFD(S) was again inactive. Comparative analysis of S1P-elicited [Ca 2ϩ ] i after preincubation with FTY720 and FTY-P for different times demonstrated a much better effectiveness of FTY720 over FTY-P. Preincubation with FTY-P had to be 10 times longer compared with nonphosphorylated FTY720 to gain similar inhibition of S1P-evoked [Ca 2ϩ ] i (Fig. 2B) . Furthermore, preincubation of mouse splenocytes with FTY720 and its active stereoisomer AAL(R) resulted in greater inhibition of Transwell chemotaxis to S1P than their phosphorylated 
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at ASPET Journals on October 2, 2017 jpet.aspetjournals.org analogs FTY-P and AFD(R) (Fig. 2C) . Whereas FTY-P was more effective in immediate down-regulation of S1P 1 -HA (Fig. 1C) , nonphosphorylated FTY720 had stronger delayed inhibitory activity after brief preincubation (Fig. 2, A-C) .
Differences of FTY720 and FTY-P in immediate and delayed S1P 1 -mediated responses could have been a result of discriminative signaling of both substances, or of metabolic interconversion. The latter was investigated using high-performance liquid chromatography separation and detection of fluorescently labeled FTY720 and FTY-P (Andréani and Grä ler, 2006) . HTC 4 cells incubated with FTY720 demonstrated massive incorporation of FTY720. They also revealed partial phosphorylation to FTY-P and its subsequent secretion (Fig. 3, A and B) . Although DMS was largely inhibiting phosphorylation of FTY720, some remaining FTY-P was still detectable within cells and in the surrounding medium (Fig.  3, A and B) . Addition of FTY-P resulted in dephosphorylation to FTY720, which mostly accumulated within cells but was also present at low concentrations in the surrounding medium (Fig. 3, C and D) . Simultaneous treatment of HTC 4 cells with phosphatase inhibitors blocked both dephosphorylation of FTY-P to FTY720 and cellular accumulation (Fig. 3, C and  D) . Thus, only nonphosphorylated FTY720 could enter and accumulate in cells, whereas FTY-P stayed in the surrounding medium.
To test the extent of metabolic interconversion and cellular exchange of FTY720 in lymphocytes, mouse splenocytes were separated into B and T cells by magnetic bead separation and subsequently incubated with FTY720 for 1 h. Incubated B cells were mixed with control T cells and vice versa and again incubated for 1 h without FTY720. After separating B and T cells again, cells and medium were analyzed for their FTY720 and FTY-P content. The incubation media contained equivalent amounts of FTY720 and FTY-P, with four times higher concentrations of FTY720 than FTY-P (Fig. 4, A and  B) . Both phosphorylated and nonphosphorylated forms were present at comparable amounts in pretreated and nontreated control T and B cells, with the exception of pretreated T cells, which carried more than twice as much FTY-P than FTY720 (Fig. 4, A and B) . Therefore, lymphocytes efficiently incorporated and phosphorylated FTY720 to FTY-P, which was efficiently exchanged with other cells via FTY720 release in the surrounding medium.
Phosphorylation renders the sphingosine analog FTY720 Fig. 2 . Sustained responses in [Ca 2ϩ ] i and chemotaxis assays after preincubation with phosphorylated and nonphosphorylated compounds. A, [Ca 2ϩ ] i of S1P 1 expressing HTC 4 cells after preincubation with 300 nM nonphosphorylated (left) and phosphorylated (right) compounds for 1 h (left) and 15 h (right), before stimulation with 100 nM S1P. Untreated and 10 M DMS-treated cells are shown as controls in one representative experiment of three. B, relative calcium flux inhibition after preincubation with 300 nM FTY-P or FTY720 for 1 to 15 h as indicated, before stimulation with 100 nM S1P. Data are means Ϯ S.E. of three independent experiments. C, inhibition of splenocyte chemotaxis to 20 nM S1P after 15-min preincubation with 300 nM FTY720, FTY-P, AAL(R), and AFD(R). Data are means Ϯ S.E. of three independent experiments. into an S1P receptor-stimulating signaling molecule. However, it is also known for other substances such as vitamins that dephosphorylation and rephosphorylation are critical events to cross cell membranes and to reach local target tissues and cells. To test whether phosphorylation-dependent differences in the local distribution of FTY720 are contributing to its in vivo efficacy, the distribution of phosphorylated and nonphosphorylated compounds in blood and lymphoid tissues was analyzed in control mice and nonresponding SK2-deficient mice. Control mice and SK2-deficient mice were treated orally with 0.3 mg/kg/day FTY720. It was sufficient to induce lymphopenia in control mice but not in SK2-deficient mice (Fig. 5A) . Consequent analysis of blood and lymphoid tissues of mice treated with 3.0 mg/kg/day FTY720 revealed very low levels of FTY-P in SK2-deficient mice. However, in control mice, FTY-P concentrations in blood cells and plasma were similar to those of FTY720 and approximately four times higher in lymphoid tissues (Fig.  5B) . Similar amounts of nonphosphorylated FTY720 were present in lymphoid tissues of both control and SK2-deficient mice (Fig. 5B) . Defective distribution of FTY720 in lymphoid tissues thus can be excluded as a potential reason for the absence of lymphopenia in FTY720-treated SK2-deficient mice. It is noteworthy that concentrations of FTY720 and FTY-P were at least 10 times higher in lymphoid tissues compared with blood cells or plasma (Fig. 5B) . Because the natural ligand S1P is most abundant in blood and lymph but hardly detectable in lymphoid tissues, accumulation of phosphorylated and nonphosphorylated FTY720 in lymphoid organs seemed to be most important for the onset of lymphopenia, with FTY-P being the active compound.
To further investigate the functional consequences of SK2 deficiency for lymphocyte migration, splenocytes from SK2-deficient mice and control mice were preincubated for 15 min with 3 to 100 nM FTY720, and they were subsequently subjected to Transwell migration experiments to S1P. Preincubation with 3 and 10 nM FTY720 caused a minor decrease of 10 and 25% of the migratory response to S1P, which was seen with both control and SK2-deficient splenocytes (Fig. 5C) . Whereas 30 and 100 nM FTY720 pretreatment completely blocked S1P-stimulated chemotaxis of control splenocytes, SK2-deficient splenocytes responded only with a further decrease of 40 to 50% compared with untreated control cells (Fig. 5C ). This pattern is reflective of the different specificities of SK1 and SK2 for FTY720, with SK2 phosphorylating high concentrations of FTY720 more efficiently than SK1. It also points out that the phosphorylating activity of SK2 for FTY720 is most important in lymphoid tissues rather than blood because of its accumulation in lymphocytes.
Discussion
FTY-P was originally described as an agonist for all S1P receptors except S1P 2 , and S1P receptor stimulation was consequently postulated as the critical event for FTY720-induced lymphopenia (Brinkmann et al., 2002; Mandala et al., 2002) . This hypothesis was subsequently challenged by the observation that FTY720 treatment rendered lymphocytes unresponsive to S1P in Transwell chemotaxis assays because of S1P 1 receptor down-regulation and degradation and the detection of severe lymphopenia in conditional S1P 1 receptor-deficient mice (Grä ler and Goetzl, 2004; Matloubian , 2004 ). Therefore, it was possible that nonphosphorylated FTY720 would alter S1P 1 receptor expression even without being phosphorylated; several phosphorylation-independent cellular effects of FTY720 were described subsequently (Coelho et al., 2007; Payne et al., 2007) . The unresponsiveness of SK2-deficient mice toward low dosages of FTY720 favored FTY-P as the active metabolite for inducing lymphopenia (Kharel et al., 2005; Zemann et al., 2006) . However, it was still possible that conversion of FTY720 to FTY-P was required to enter lymphoid tissues instead of lymphocytes being activated. The abundance of FTY720 in lymphoid tissues of treated SK2-deficient mice now demonstrates that this is not the case (Fig. 5B ). Although FTY720 itself was able to enter lymphoid tissues without SK2 activity, it was not inducing lymphopenia in SK2-deficient mice (Fig. 5A ). Therefore, FTY-P is clearly responsible for blocking lymphocyte egress.
The missing phenotype of low FTY720 dosages in SK2-deficient mice was interpreted in favor for S1P 1 receptor stimulation rather than down-regulation and inhibition as the cause for FTY720-induced lymphopenia (Kharel et al., 2005; Zemann et al., 2006) . Transwell chemotaxis studies with splenocytes from SK2-deficient mice, however, reveal that inhibition of S1P receptor signaling in lymphocytes is also impaired by SK2 deficiency (Fig. 5C ). The reason for the ineffectiveness of S1P 1 receptor antagonists to induce lymphopenia is most probably their competition with high amounts of S1P in blood and lymph. Agonists that are able to enter lymphoid tissues, however, can activate the S1P 1 receptor on sinus-lining endothelial cells and prematurely down-regulate it on lymphocytes at very low concentrations. Therefore, the important interaction of S1P 1 receptor agonists for inducing lymphopenia does not take place in blood or lymph but in lymphoid tissues. This view is also supported by 10 times higher concentrations of FTY720 and FTY-P in lymphoid tissues compared with blood (Fig. 5B) . Because SK2 has a similar K m value (13 Ϯ 1 versus 11 Ϯ 1 M) but a six times higher V max value (170 Ϯ 5 versus 29 Ϯ 1 pmol/ min/mg) for FTY720, higher FTY720 concentrations will preferentially be phosphorylated by SK2 (Paugh et al., 2003) .
Small molecules have only a brief half-life in vivo and will be rapidly distributed and washed out by the lymphatic and circulatory system. FTY720 is an important exception because it is efficiently taken up by cells (Fig. 3B) . Cellular FTY720 can function as a repository and as a substrate for sphingosine kinases. As such, it is gradually phosphorylated to FTY-P and secreted, which sets the basis for the described long-term efficacy of this immunomodulator. It also explains the higher efficiency of FTY720 and AAL(R) compared with their phosphorylated metabolites to inhibit S1P-elicited [Ca 2ϩ ] i and chemotaxis (Fig. 2 , A-C) and to induce prolonged down-regulation of S1P 1 -HA after preincubation (Fig. 1C) .
The hypothesis that FTY-P-induced internalization rather than stimulation of the S1P 1 receptor in lymphocytes is causing lymphopenia was challenged by the observation that pretreatment of adoptively transferred lymphocytes with FTY720 was not sufficient to retain them in SLOs (Pabst et al., 2006) . Only FTY720 treatment of recipient mice had the desired effect. This lack of a direct effect on lymphocytes, however, can be explained by the observation that FTY720 undergoes cellular exchange and will not stay in pretreated lymphocytes (Fig. 4, A and B) . Once FTY720 and FTY-P fade away, the activity of FTY-P and the long-term storage effect of FTY720 are gone, which will render every preincubation effort ineffective.
Based on the data presented, nonphosphorylated FTY720 enters and accumulates in lymphocytes, which results in a 10 times higher concentration in lymphoid tissues compared with blood. FTY720 itself is inactive and needs to be phosphorylated by sphingosine kinases to induce lymphopenia. FTY-P is most efficiently generated by SK2 at high FTY720 concentrations found in lymphoid tissues, generating equally high concentrations of FTY-P (Fig. 6) . The latter is then gradually released by lymphocytes and acts in the local lymphoid tissue environment by prematurely down-regulating the S1P 1 receptor on lymphocytes and activating the S1P 1 receptor on sinus-lining endothelial cells. This prevents lymphocytes from sensing S1P in blood and lymph as the required signal for egress, and it leads to the closure of postulated endothelial cell portals. Both events block lymphocyte egress from thymus and SLOs and consequently result in lymphopenia. Fig. 6 . Proposed mechanism for FTY720-induced lymphopenia. The prodrug FTY720 is incorporated by cells and accumulates intracellularly. SK2 phosphorylates FTY720 to FTY-P, with a 6 times higher V max value than that of SK1. Therefore, high cellular amounts of FTY720 will be favorably phosphorylated by SK2. Cells secrete FTY-P into the intercellular space of thymus and SLOs. Extracellular FTY-P down-regulates S1P 1 on lymphocytes (top left) and activates S1P 1 on sinus-lining endothelial cells (bottom left). This prevents a chemotactic stimulus via the S1P-S1P 1 axis and closes postulated stromal portals. Both events inhibit egress of lymphocytes into blood and lymph and induce lymphopenia. FTY-P may also be dephosphorylated again by a phosphatase (Phosph.) to FTY720, which is able to enter cells again. Cellular accumulation and storage of FTY720 together with SK2-catalyzed phosphorylation and secretion of FTY-P is the reason for prolonged efficacy of this immunomodulator. 
